Biopharmaceutical company in clinical stage: Peak Bio, Inc. (PKBO)

Peak Bio, Inc. (NASDAQ: PKBO), founded in 2020, headquartered in Pleasanton, California, USA, with 21 full-time employees, is a clinical Biopharmaceutical Company , focusing on the development of treatment methods to address major unmet needs in oncology and inflammation.

The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/pkbo.html

Peak Bio, Inc. (PKBO)

Peak Bio is a biopharmaceutical company at the clinical stage. Its management team has 50 years of industry experience in the field of small molecules, antibodies and antibody drug conjugates (ADC), and has built a successful company to create first-class therapies. The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/pkbo.html

Peak Bio's pipeline focuses on developing drugs to treat tumor and inflammatory diseases. The company's inflammatory treatment candidate drug pipeline is dominated by PHP-303, which is currently in the phase II preparation stage in the AATD, and acts by inhibiting the biological activity of neutrophil elastase. The company's product line also includes an antibody drug conjugate platform, which focuses on the development of therapies for tumor indications. The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/pkbo.html

PHP-303 is a small molecule. At present, it is waiting for the phase II dose clinical study on the orphan disease Alpha1 antitrypsin deficiency (AATD). It is expected that the mid-term safety results will be achieved by the end of 2023. The main candidate product of Peak Bio, PHP-303, is a small molecule. At present, it is waiting for the phase II dose clinical study on the orphan disease Alpha1 antitrypsin deficiency (AATD). It is expected that the mid-term safety results will be obtained by the end of 2023. After the single incremental dose (SAD) and multiple incremental dose (MAD) phase I trials proved the dose dependent pharmacokinetics and reached the pre clinical recommended phase II dose (RP2D), the company has successfully provided patients with higher doses of PHP-303) safely. The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/pkbo.html

PHP-303 – 5th Generation Best In Class Neutrophil Elastase (NE) Inhibitor : PHP-303 is an oral QD, reversible and highly selective small molecule, which solves the toxicity and insufficient efficacy of the previous generation of neutrophil elastase inhibitor by inhibiting the biological activity of the enzyme. The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/pkbo.html

• PHP-303 is from Bayer Acquired and improved to become an ideal solution, applicable to the situation involving NE imbalance, with good tolerance and security/PK data.
• PHP-303 is a first-class phase II ready NE inhibitor, targeting AATD and ARDS diseases, in which chronic inflammatory imbalance and NE are important determinants of disease progression

Antibody Drug Conjugate Platform : Different from competitors, Peak Bio's ADC method uses the immune system to enhance tumor killing activity, reduce the number of treatment cycles, and generate new toxins through proprietary methods to increase toxicity. The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/pkbo.html

• Compared with competitors approved by FDA, Peak Bio's most advanced ADC candidate drug targeting Trop2 shows excellent junction stability and in vivo activity, has excellent specificity for cancer cells, and has a unique ability to generate new epitopes and cooperate with I/O therapy.
• The risk reduction steps (such as manufacturability assessment) showed that there was no responsibility that might hinder the production of Peak Bio Trop2 antibody. The safety study showed that the ADC of Peak Bio was safely tolerated in the repeated dose preclinical primate study.
• Peak Bio is working hard to verify other solid tumor targets to cooperate with the company's current toxins and other new toxins to further consolidate its oncology product portfolio.

Peak Bio, Inc. (PKBO) is listed

On April 28, 2022, Peak Bio Co., Ltd., a biopharmaceutical company focusing on the clinical stage of developing next-generation therapies for tumor and inflammatory diseases, and Special purpose acquisition company Ignyte Acquisition Corp. (NASDAQ code: IGNY) announced today that they have signed the final business merger agreement. After the completion of the transaction, Ignyte will be renamed Peak Bio, Inc., led by Hoyoung Huh, MD, CEO of Peak Bio. The merged company is expected to be listed on NASDAQ with the stock code of "PKBO". The transaction valued the combined company at $278 million. The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/pkbo.html

A group of healthcare investors, including the existing Peak Bio shareholders and Palo Alto Investors, have committed to invest $25 million in common stock PIPE at a price of $10.00 per share. After the merger, the total transaction income that the company can obtain at the end of the transaction is about $82.5 million (assuming no redemption). The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/pkbo.html

The transaction has been approved by the board of directors of Ignyte, the board of directors of Peak Bio and the shareholders of Peak Bio, and is expected to be completed in the third quarter of 2022, but needs to be approved by the shareholders of Ignyte. The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/pkbo.html

On October 27, 2022, Ignyte Acquisition Corp. (NASDAQ stock code: IGNY) announced that its shareholders approved the merger with Peak Bio, a biopharmaceutical company, at the special meeting on October 25. The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/pkbo.html

Peak Bio, Inc. (PKBO) US equity investment

On March 5, 2024, Akari Therapeutics (NASDAQ stock code: AKTX) and Peak Bio (OTC trading code: PKBO) have completed the equivalent merger of all stock transactions. Peak Bio Delisting 。